11 – 20 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease
(
- Contribution to journal › Article
-
Mark
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
(
- Contribution to journal › Article
-
Mark
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
(
- Contribution to journal › Scientific review
- 2011
-
Mark
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2010
-
Mark
Involvement of non-dopaminergic systems in L-DOPA-induced dyskinsia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
(
- Contribution to journal › Article
-
Mark
Differential molecular and behavioural response to L-DOPA in mice injected with 6-hydroxydopamine in the striatum or in the medial forebrain bundle
2010)(
- Contribution to conference › Poster
- 2009
-
Mark
Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application
(
- Thesis › Doctoral thesis (compilation)
- 2008
-
Mark
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article